AU2003210447B2 - Nitric oxide donors for treatment of disease and injury - Google Patents

Nitric oxide donors for treatment of disease and injury Download PDF

Info

Publication number
AU2003210447B2
AU2003210447B2 AU2003210447A AU2003210447A AU2003210447B2 AU 2003210447 B2 AU2003210447 B2 AU 2003210447B2 AU 2003210447 A AU2003210447 A AU 2003210447A AU 2003210447 A AU2003210447 A AU 2003210447A AU 2003210447 B2 AU2003210447 B2 AU 2003210447B2
Authority
AU
Australia
Prior art keywords
cells
rats
sildenafil
brain
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003210447A
Other languages
English (en)
Other versions
AU2003210447A1 (en
Inventor
Michael Chopp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry Ford Health System
Original Assignee
Henry Ford Health System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry Ford Health System filed Critical Henry Ford Health System
Publication of AU2003210447A1 publication Critical patent/AU2003210447A1/en
Application granted granted Critical
Publication of AU2003210447B2 publication Critical patent/AU2003210447B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2003210447A 2002-01-04 2003-01-06 Nitric oxide donors for treatment of disease and injury Ceased AU2003210447B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34547802P 2002-01-04 2002-01-04
US60/345,478 2002-01-04
PCT/US2003/000323 WO2003056899A2 (en) 2002-01-04 2003-01-06 Nitric oxide donors for treatment of disease and injury

Publications (2)

Publication Number Publication Date
AU2003210447A1 AU2003210447A1 (en) 2003-07-24
AU2003210447B2 true AU2003210447B2 (en) 2008-02-07

Family

ID=23355218

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003210447A Ceased AU2003210447B2 (en) 2002-01-04 2003-01-06 Nitric oxide donors for treatment of disease and injury

Country Status (9)

Country Link
US (2) US20050143388A1 (enExample)
EP (1) EP1469852A4 (enExample)
JP (2) JP4545440B2 (enExample)
CN (1) CN1638775A (enExample)
AU (1) AU2003210447B2 (enExample)
CA (1) CA2471147C (enExample)
IL (1) IL162850A0 (enExample)
WO (1) WO2003056899A2 (enExample)
ZA (1) ZA200405507B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007010337A2 (de) * 2005-07-15 2007-01-25 Proxomed Medizintechnik Gmbh Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von adipositas, sowie abgabesysteme für dieselben
JP2009521403A (ja) * 2005-11-14 2009-06-04 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク Ｍｒｉによる神経発生の相関の画像法
US8841300B2 (en) 2006-10-02 2014-09-23 Jerry M. Held Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
CN101754756A (zh) * 2007-05-18 2010-06-23 维瓦斯公司 包含磷酸二酯酶-5抑制剂的新组合和它们的用途
US20110104100A1 (en) * 2007-10-04 2011-05-05 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
US20100316622A1 (en) * 2007-11-02 2010-12-16 University Of Miami Diagnosis and treatment of cardiac disorders
EA029892B1 (ru) 2012-04-25 2018-05-31 Такеда Фармасьютикал Компани Лимитед Азотсодержащее гетероциклическое соединение
JP6205356B2 (ja) 2012-07-13 2017-09-27 武田薬品工業株式会社 複素環化合物
ES2635016T3 (es) * 2013-03-01 2017-10-02 Fundación Para La Investigación Médica Aplicada Nuevos compuestos como inhibidores duales de fosfodiesterasas e histonas deacetilasas
EP2975031A4 (en) 2013-03-14 2017-04-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3018126A4 (en) 2013-07-03 2016-12-07 Takeda Pharmaceuticals Co HETEROCYCLIC CONNECTION
JP6411342B2 (ja) 2013-07-03 2018-10-24 武田薬品工業株式会社 アミド化合物
US10297661B2 (en) * 2017-06-30 2019-05-21 Taiwan Semiconductor Manufacturing Co., Ltd. High voltage resistor device
WO2023109513A1 (zh) * 2021-12-14 2023-06-22 真奥金银花药业有限公司 爱地那非或其盐在制备预防或治疗缺血性脑损伤的药物中的应用
TWI879058B (zh) * 2023-08-31 2025-04-01 未來新藥股份有限公司 Pde5抑制劑組合於促進神經突生長之新穎用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI964113L (fi) * 1994-04-15 1996-10-14 Iyo Masaomi Lääkekoostumus hoitamaan tardiivia dyskinesiaa ja sen käyttö
US5827740A (en) * 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
CA2279651A1 (en) * 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6043223A (en) * 1997-11-12 2000-03-28 The Regents Of The University Of California Enhanced opening of abnormal brain tissue capillaries
DE19834507A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
AU780994B2 (en) 1999-05-14 2005-04-28 Henry Ford Health System Bone marrow transplantation for treatment of stroke
IL147112A0 (en) * 1999-06-14 2002-08-14 Ford Henry Health System Nitric oxide donors for inducing neurogenesis
IL152925A (en) 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
US6271228B1 (en) 2000-04-28 2001-08-07 Pfizer Inc. Blood pressure stabilization during hemodialysis
US7947731B2 (en) * 2000-08-10 2011-05-24 Cold Spring Harbor Laboratory Augmented cognitive training

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders

Also Published As

Publication number Publication date
EP1469852A4 (en) 2009-12-02
CA2471147C (en) 2010-08-10
US20050143388A1 (en) 2005-06-30
WO2003056899A2 (en) 2003-07-17
US20120009152A1 (en) 2012-01-12
ZA200405507B (en) 2005-05-25
CN1638775A (zh) 2005-07-13
IL162850A0 (en) 2005-11-20
JP4545440B2 (ja) 2010-09-15
CA2471147A1 (en) 2003-07-17
WO2003056899A3 (en) 2003-11-27
WO2003056899A9 (en) 2004-04-15
AU2003210447A1 (en) 2003-07-24
JP2005514406A (ja) 2005-05-19
EP1469852A2 (en) 2004-10-27
JP2009256374A (ja) 2009-11-05

Similar Documents

Publication Publication Date Title
US20120009152A1 (en) Nitric oxide donors for treatment of disease and injury
US9394520B2 (en) Expansion of hematopoietic stem cells
US7514261B2 (en) Platelet-derived growth factor protection of cardiac myocardium
US7658951B2 (en) Method of improving cardiac function of a diseased heart
JP2010018627A (ja) 血管の形成ならびに血管新生および栄養因子の生産に使用するための骨髄間質細胞に由来する物質
JP2004529916A (ja) パーキンソン病の治療において神経栄養活性化合物と組み合わせたアデノシンａ２ａレセプターアンタゴニスト
KR102622408B1 (ko) Opa1 억제에 의한 조골세포 활성화를 통한 골형성 촉진 유도용 또는 골질환 치료용 조성물
JP5500773B2 (ja) 副甲状腺ホルモン受容体の活性化並びに幹細胞及び前駆細胞の増殖
US20250009936A1 (en) Tissue regeneration with in vitro activated effector cells
JP2004123679A (ja) 好酸球カチオン性タンパク質を含有する組成物
CN113507934A (zh) 用于治疗脑内出血的多潜能成体祖细胞
AU2002339944A1 (en) Cardiac transplantation of stem cells for the treatment of heart failure
AU2002332486A1 (en) Platelet-derived growth factor protection of cardiac myocardium

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired